A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MA / matrix

[Related PubMed/MEDLINE]
Total Number of Papers: 211
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MA  (>> Co-occurring Abbreviation)
Long Form:   matrix
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Analysis of HIV-1 matrix-envelope cytoplasmic tail interactions. CTs, Env, MACA, PM, PrGag
2019 Dominant negative MA-CA fusion protein is incorporated into HIV-1 cores and inhibits nuclear entry of viral preintegration complexes. CA, NC
2019 HIV-1 matrix mutations that alter gag membrane binding modulate mature core formation and post-entry events. ---
2019 Relationships between MA-RNA binding in cells and suppression of HIV-1 Gag mislocalization to intracellular membranes. HBR, PM
2019 Replication of HIV-1 envelope protein cytoplasmic domain variants in permissive and restrictive cells. CTs, Env, PMs, WT
2019 Retroviral Gag protein-RNA interactions: Implications for specific genomic RNA packaging and virion assembly. gRNA, NC
2019 Serial Femtosecond X-Ray Diffraction of HIV-1 Gag MA-IP6 Microcrystals at Ambient Temperature. HIV-1, SFX, XFEL
2019 Solution Conformation of Bovine Leukemia Virus Gag Suggests an Elongated Structure. BLV, CA, NC
2019 Specific inter-domain interactions stabilize a compact HIV-1 Gag conformation. MD, MHR
10  2018 HIV-1 Matrix Protein Interactions with tRNA: Implications for Membrane Targeting. ---
11  2018 Human T-cell leukemia virus type 1 Gag domains have distinct RNA-binding specificities with implications for RNA packaging and dimerization. DIS, gRNA, HTLV-1, NC
12  2018 Lipid biosensor interactions with wild type and matrix deletion HIV-1 Gag proteins. Env, PM, PrGag, WT
13  2018 Structural basis for targeting avian sarcoma virus Gag polyprotein to the plasma membrane for virus assembly. ASV, IPs, PM
14  2018 The matrix domain of the Gag protein from avian sarcoma virus contains a PI(4,5)P2-binding site that targets Gag to the cell periphery. ASV, myr, PH-PLC, PM, Spry2, VLPs
15  2017 Cholesterol Promotes Protein Binding by Affecting Membrane Electrostatics and Solvation Properties. Chol, RSV
16  2017 FRET analysis of HIV-1 Gag and GagPol interactions. FRET
17  2017 Increasing the CpG dinucleotide abundance in the HIV-1 genomic RNA inhibits viral replication. gRNA, HIV-1, nt
18  2017 Inhibition of HIV-1 Gag-membrane interactions by specific RNAs. HBR, PM
19  2016 Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation. Env
20  2016 Equine Infectious Anemia Virus Gag Assembly and Export Are Directed by Matrix Protein through trans-Golgi Networks and Cellular Vesicles. EIAV, PM, TGN
21  2016 Functional Equivalence of Retroviral MA Domains in Facilitating Psi RNA Binding Specificity by Gag. 5'UTR, gRNA, HIV-1, NC, RSV
22  2016 HIV-1 Gag, Envelope, and Extracellular Determinants Cooperate To Regulate the Stability and Turnover of Virological Synapses. CT, Env, VSs
23  2016 Investigation of the HIV-1 matrix interactome during virus replication. HIV-1, SWATH, YB-1
24  2016 Molecular Determinants Directing HIV-1 Gag Assembly to Virus-Containing Compartments in Primary Macrophages. 5ptaseIV, PM, VCCs
25  2016 Myristoylation drives dimerization of matrix protein from mouse mammary tumor virus. MMTV, PM
26  2016 Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein. ---
27  2016 The matrix domain contributes to the nucleic acid chaperone activity of HIV-2 Gag. NAC, NC, Psi
28  2016 Trimer Enhancement Mutation Effects on HIV-1 Matrix Protein Binding Activities. CTs, Env, WT
29  2015 Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins. ---
30  2015 Elucidating the mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective for gag membrane targeting and envelope glycoprotein incorporation. Env, HIV
31  2015 HIV-1 Exploits the Host Factor RuvB-like 2 to Balance Viral Protein Expression. Env, RVB2
32  2015 HIV-1 matrix domain removal ameliorates virus assembly and processing defects incurred by positive nucleocapsid charge elimination. NC
33  2015 Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein. CA, DYNLT1, HIV-1, IN, KD, RT
34  2015 Live-cell observation of cytosolic HIV-1 assembly onset reveals RNA-interacting Gag oligomers. CA, NC
35  2015 Membrane Binding of the Rous Sarcoma Virus Gag Protein Is Cooperative and Dependent on the Spacer Peptide Assembly Domain. CA, NC, PM, SPA
36  2015 NMR structure of the myristylated feline immunodeficiency virus matrix protein. FIV
37  2015 No-Go'ing Back: Co-opting RVB-2 to Control HIV-1 Gene Expression and Immune Response. Env
38  2015 Structural and molecular determinants of HIV-1 Gag binding to the plasma membrane. PM
39  2015 The HIV-1 nucleocapsid protein recruits negatively charged lipids to ensure its optimal binding to lipid membranes. CA, LUVs, NC, PM
40  2014 A temporospatial map that defines specific steps at which critical surfaces in the Gag MA and CA domains act during immature HIV-1 capsid assembly in cells. CA, CA-CTD
41  2014 Deletions in the fifth alpha helix of HIV-1 matrix block virus release. ---
42  2014 Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs. CA, FP, HIV, PR
43  2014 In vitro analysis of human immunodeficiency virus particle dissociation: gag proteolytic processing influences dissociation kinetics. CA, FRET, NC
44  2014 Mechanistic differences between nucleic acid chaperone activities of the Gag proteins of Rous sarcoma virus and human immunodeficiency virus type 1 are attributed to the MA domain. GagDeltap6, gRNA, HIV-1, IPs, NA, NC, PBS, RSV
45  2014 Membrane binding and subcellular localization of retroviral Gag proteins are differentially regulated by MA interactions with phosphatidylinositol-(4,5)-bisphosphate and RNA. 5ptaseIV, GagLZ, HERV-K, HTLV-1, MLV, PM, RSV, VLP
46  2014 Retrovirus-specific differences in matrix and nucleocapsid protein-nucleic acid interactions: implications for genomic RNA packaging. BLV, gRNA, HTLV-1, NA, NC
47  2014 Role of the nucleocapsid region in HIV-1 Gag assembly as investigated by quantitative fluorescence-based microscopy. CA, NC, PM
48  2014 Solution structure of calmodulin bound to the binding domain of the HIV-1 matrix protein. CaM, HIV-1
49  2014 Structural elements in the Gag polyprotein of feline immunodeficiency virus involved in Gag self-association and assembly. CA, FIV, NC, VLPs
50  2014 The role of matrix in HIV-1 envelope glycoprotein incorporation. Env
51  2014 The roles of lipids and nucleic acids in HIV-1 assembly. CA, NC, PM, PrGag
52  2014 Use of principal components analysis and protein microarray to explore the association of HIV-1-specific IgG responses with disease progression. CA, IN, PCA, RT, SU, TM
53  2014 Virus particle release from glycosphingolipid-enriched microdomains is essential for dendritic cell-mediated capture and transfer of HIV-1 and henipavirus. DCs, GSL, HIV-1, mDCs
54  2013 Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein. SPR
55  2013 Distinct binding interactions of HIV-1 Gag to Psi and non-Psi RNAs: implications for viral genomic RNA packaging. gRNA, NC
56  2013 Elements in HIV-1 Gag contributing to virus particle assembly. CA, NA, NC
57  2013 Evidence that Vpu modulates HIV-1 Gag-envelope interaction towards envelope incorporation and infectivity in a cell type dependent manner. Env, MDM, PBMC
58  2013 Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure. Env
59  2013 HIV-1 Gag associates with specific uropod-directed microdomains in a manner dependent on its MA highly basic region. HBR, UDMs
60  2013 Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein. ---
61  2013 Inositol phosphates compete with nucleic acids for binding to bovine leukemia virus matrix protein: implications for deltaretroviral assembly. BLV, HIV-1, PM, ssDNA
62  2013 Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation. HIV-1, RNAi, TIP47
63  2013 Trio engagement via plasma membrane phospholipids and the myristoyl moiety governs HIV-1 matrix binding to bilayers. HIV-1, PC, PE, PM, PS
64  2012 A highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particles. Env, HIV-1
65  2012 A small-molecule-controlled system for efficient pseudotyping of prototype foamy virus vectors. FV, HD, HDD, HIV, MTD, VSV-G
66  2012 Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins. ---
67  2012 Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. CA, HIV-1, MDR, NC, PR, SP1
68  2012 CRM1-dependent trafficking of retroviral Gag proteins revisited. HIV-1, RSV
69  2012 Feline immunodeficiency virus Gag is a nuclear shuttling protein. CA, FIV, HIV-1, NC-p2
70  2012 HIV-1 Gag protein can sense the cholesterol and acyl chain environment in model membranes. Gag
71  2012 In vitro assembly of virus-like particles of a gammaretrovirus, the murine leukemia virus XMRV. CA, CANC, MLV, NC, VLP
72  2012 On the Primary Ionization Mechanism(s) in Matrix-Assisted Laser Desorption Ionization. ---
73  2012 Protease cleavage leads to formation of mature trimer interface in HIV-1 capsid. CA, cryo-EM, NC
74  2012 Role of the HIV-1 Matrix Protein in Gag Intracellular Trafficking and Targeting to the Plasma Membrane for Virus Assembly. HIV-1, myr, PM
75  2012 The HIV-1 matrix protein does not interact directly with the protein interactive domain of AP-3delta. HIV-1
76  2011 Gag localization and virus-like particle release mediated by the matrix domain of human T-lymphotropic virus type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than those mediated by the matrix domain of HIV-1 Gag. 5ptaseIV, HIV-1, HTLV-1, PM
77  2011 HIV-1 matrix protein binding to RNA. HIV-1, PrGag
78  2011 HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. BVM, CA, NC, SP1
79  2011 Mapping of the self-interaction domains in the simian immunodeficiency virus Gag polyprotein. CA, NC, SIV
80  2011 Matrix domain modulates HIV-1 Gag's nucleic acid chaperone activity via inositol phosphate binding. CA, IP, NC, PM
81  2011 Phosphoinositides direct equine infectious anemia virus gag trafficking and release. EIAV, HIV-1, NMR, PI, VLPs
82  2011 The cellular protein lyric interacts with HIV-1 Gag. HIV-1, NC
83  2011 Tracking and quantitation of fluorescent HIV during cell-to-cell transmission. CA, GFP, VLP
84  2010 Changes in the accessibility of the HIV-1 Integrase C-terminus in the presence of cellular proteins. HIV-1, IN, PIC
85  2010 Electrostatic interactions and binding orientation of HIV-1 matrix studied by neutron reflectivity. ---
86  2010 Intracellular localization of human immunodeficiency virus type 1 Gag and GagPol products and virus particle release: relationship with the Gag-to-GagPol ratio. HIV, PR
87  2010 Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. HBR
88  2010 Structural basis of the association of HIV-1 matrix protein with DNA. PIC
89  2010 Targeting of murine leukemia virus gag to the plasma membrane is mediated by PI(4,5)P2/PS and a polybasic region in the matrix. MuLV
90  2009 Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids. HIV-1, PM, PrGag
91  2009 HIV-1 matrix dependent membrane targeting is regulated by Gag mRNA trafficking. BiFC, HBV, PRE
92  2009 HIV-1 matrix organizes as a hexamer of trimers on membranes containing phosphatidylinositol-(4,5)-bisphosphate. CA, Env, HIV-1, Myr, PrGag
93  2009 Matrix mediates the functional link between human immunodeficiency virus type 1 RNA nuclear export elements and the assembly competency of Gag in murine cells. HIV-1, NC, RRE
94  2009 Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. HIV-1
95  2009 Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector. CVB3, HIV-1
96  2009 Real-time RT-PCR for detection of equine influenza and evaluation using samples from horses infected with A/equine/Sydney/2007 (H3N8). DSe, EI, HA, IVA, RT-PCR
97  2009 Structural studies of HIV-1 Gag p6ct and its interaction with Vpr determined by solution nuclear magnetic resonance. Gag, HIV-1, MD, MVB, p6ct, PWR, Vpr
98  2009 Visualizing fusion of pseudotyped HIV-1 particles in real time by live cell microscopy. Env, HIV-1
99  2008 1H, 13C, and 15N resonance assignment of the N-terminal domain of Mason-Pfizer monkey virus capsid protein, CA 1-140. CA, CTD, MPMV, NC, NTD
100  2008 Analysis of human immunodeficiency virus matrix domain replacements. MBD, PrGag, VLPs